Lonapegsomatropin
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Lonapegsomatropin, sold under the brand name Skytrofa, is a human growth hormone used for the treatment of growth hormone deficiency.[1][3] Lonapegsomatropin is a prodrug of somatropin.[1]
Trade namesSkytrofa
Other namesLonapegsomatropin-tcgd; rhGH-PEG; ACP-011; ΤransConPEG hGh; WHO-10598
| Clinical data | |
|---|---|
| Trade names | Skytrofa |
| Other names | Lonapegsomatropin-tcgd; rhGH-PEG; ACP-011; ΤransConPEG hGh; WHO-10598 |
| License data | |
| Routes of administration | Subcutaneous injection |
| Drug class | Growth hormone receptor agonist |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChem SID | |
| DrugBank | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C1051H1627N269O317S9[C2H4O]4n |
Lonapegsomatropin was approved for medical use in the United States in August 2021,[1][2][5] and in the European Union in January 2022.[3]
Medical uses
Lonapegsomatropin is a growth hormone therapy indicated to treat growth hormone deficiency.[1][3]
History
The US Food and Drug Administration granted the application for lonapegsomatropin orphan drug designation.[6]
